Pasithea Therapeutics Corp.(KTTA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

KTTA Pasithea Therapeutics Corp.

Post-Mkt 04-30 17:07:54 EDT

0.6947

+0.0060

+0.87%

盘后0.7085

+0.0138+1.99%

16:42 EDT

High0.7099	Low0.6802	Vol228.32K
Open0.6900	D1 Closing0.6887	Amplitude4.31%
Mkt Cap17.33M	Tradable Cap11.64M	Total Shares24.94M
T/O158.43K	T/O Rate1.36%	Tradable Shares16.75M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"KTTA","market":"US","secType":"STK","nameCN":"Pasithea Therapeutics Corp.","latestPrice":0.6947,"timestamp":1777579200000,"preClose":0.6887,"halted":0,"volume":228315,"hourTrading":{"tag":"盘后","latestPrice":0.7085,"preClose":0.6947,"latestTime":"16:42 EDT","volume":1768,"amount":1228.3676808,"timestamp":1777581766215,"change":0.0138,"changeRate":0.019865,"amplitude":0.019865},"delay":0,"changeRate":0.008712066211703217,"floatShares":16753400,"shares":24939899,"eps":-2.91,"marketStatus":"Post-Mkt","change":0.006,"latestTime":"04-30 17:07:54 EDT","open":0.69,"high":0.7099,"low":0.6802,"amount":158434.81060199998,"amplitude":0.043125,"askPrice":0.73,"askSize":128,"bidPrice":0.65,"bidSize":98,"shortable":3,"etf":0,"ttmEps":-2.91,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1777593600000},"marketStatusCode":4,"adr":0,"listingDate":1628654400000,"exchange":"NASDAQ","adjPreClose":0.6887,"preHourTrading":{"tag":"盘前","latestPrice":0.7099,"preClose":0.6887,"latestTime":"09:12 EDT","volume":39,"amount":27.6857022,"timestamp":1777554778434,"change":0.0212,"changeRate":0.030783,"amplitude":0.000145},"postHourTrading":{"tag":"盘后","latestPrice":0.7085,"preClose":0.6947,"latestTime":"16:42 EDT","volume":1768,"amount":1228.3676808,"timestamp":1777581766215,"change":0.0138,"changeRate":0.019865,"amplitude":0.019865},"volumeRatio":1.065207},"requestUrl":"/m/hq/s/KTTA/tweets","defaultTab":"tweets","newsList":[{"id":"2629279997","title":"Pasithea Therapeutics Price Target Maintained With a $3.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2629279997","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629279997?lang=en_us&edition=fundamental","pubTime":"2026-04-21 00:37","pubTimestamp":1776703020,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/KTTA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 20, 2026 12:37 ET (16:37 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KTTA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628742602","title":"Pasithea Therapeutics Announces Grant of Rare Pediatric Disease Designation (RPDD) by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1)","url":"https://stock-news.laohu8.com/highlight/detail?id=2628742602","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628742602?lang=en_us&edition=fundamental","pubTime":"2026-04-20 19:01","pubTimestamp":1776682860,"startTime":"0","endTime":"0","summary":"Rare Pediatric Disease Designation may render Pasithea eligible to receive a Priority Review Voucher (PRV)MIAMI, April  20, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasith","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/20/3276869/0/en/Pasithea-Therapeutics-Announces-Grant-of-Rare-Pediatric-Disease-Designation-RPDD-by-FDA-to-PAS-004-for-Treatment-of-Neurofibromatosis-Type-1-NF1.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4096","KTTA","LU1169589451.USD","BK4023","LU1169590202.USD","BK4588","BK4585","BK4218","BK4181","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628373304","title":"Pasithea Therapeutics files Form 3 beneficial ownership statement for Coastlands Capital LP","url":"https://stock-news.laohu8.com/highlight/detail?id=2628373304","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628373304?lang=en_us&edition=fundamental","pubTime":"2026-04-18 09:45","pubTimestamp":1776476744,"startTime":"0","endTime":"0","summary":"Coastlands Capital LP filed Form 3 disclosing 10% ownership in Pasithea Therapeutics  tied to event date April 9, 2026.Filing shows indirect beneficial ownership of 3,735,035 shares of common stock.Coastlands also reported indirect ownership of pre-funded warrants exercisable for 11,233,334 shares at an exercise price of USD 0.001.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pasithea Therapeutics Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 17, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260418:nNDL6FCwLR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KTTA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624768715","title":"Pasithea Therapeutics Corp reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2624768715","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624768715?lang=en_us&edition=fundamental","pubTime":"2026-04-03 05:01","pubTimestamp":1775163673,"startTime":"0","endTime":"0","summary":"Pasithea Therapeutics Corp reports results for the quarter ended December 31 - Earnings SummaryPasithea Therapeutics Corp KTTA.OQ reported a quarterly adjusted loss of 79 cents per share for the quart","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nL8N40L21L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KTTA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624590888","title":"Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Causing Significant Morbidity","url":"https://stock-news.laohu8.com/highlight/detail?id=2624590888","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624590888?lang=en_us&edition=fundamental","pubTime":"2026-04-01 19:01","pubTimestamp":1775041260,"startTime":"0","endTime":"0","summary":"Fast Track designation is one of the FDA’s expedited programs meant to facilitate development and expedite review of new drugs that have the potential to address an unmet medical need in the treatment","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/01/3266483/0/en/Pasithea-Therapeutics-Announces-Grant-of-Fast-Track-Designation-by-FDA-to-PAS-004-for-Treatment-of-Neurofibromatosis-Type-1-NF1-Associated-Plexiform-Neurofibromas-PN-Causing-Signif.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1169590202.USD","BK4096","KTTA","BK4588","BK4139","BK4218","BK4023","BK4585","LU1169589451.USD","BK4181"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624537335","title":"Pasithea Therapeutics Corp  expected to post a loss of 45 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2624537335","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624537335?lang=en_us&edition=fundamental","pubTime":"2026-04-01 04:02","pubTimestamp":1774987340,"startTime":"0","endTime":"0","summary":"Pasithea Therapeutics Corp  expected to post a loss of45cents a share - Earnings Preview Pasithea Therapeutics Corp KTTA.OQ KTTA.O is expected to  report resultson May 13 (estimated) for the period en","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nL8N40J2D1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KTTA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622277370","title":"Positive Signs As Multiple Insiders Buy Pasithea Therapeutics Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2622277370","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622277370?lang=en_us&edition=fundamental","pubTime":"2026-03-25 18:09","pubTimestamp":1774433350,"startTime":"0","endTime":"0","summary":"Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ktta/pasithea-therapeutics/news/positive-signs-as-multiple-insiders-buy-pasithea-therapeutic","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ktta/pasithea-therapeutics/news/positive-signs-as-multiple-insiders-buy-pasithea-therapeutic","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["KTTA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621775104","title":"Pasithea Therapeutics Corp  expected to post a loss of 18 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2621775104","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621775104?lang=en_us&edition=fundamental","pubTime":"2026-03-21 04:38","pubTimestamp":1774039087,"startTime":"0","endTime":"0","summary":"Pasithea Therapeutics Corp  expected to post a loss of18cents a share - Earnings Preview Pasithea Therapeutics Corp KTTA.OQ KTTA.O is expected to  report resultson March 23 (estimated) for the period ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260320:nL8N4082BC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KTTA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613521848","title":"Pasithea Therapeutics Receives Nasdaq Minimum Bid Price Notice","url":"https://stock-news.laohu8.com/highlight/detail?id=2613521848","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613521848?lang=en_us&edition=fundamental","pubTime":"2026-02-21 06:36","pubTimestamp":1771626999,"startTime":"0","endTime":"0","summary":"Pasithea Therapeutics Corp ( ($KTTA) ) has provided an update. On February 20, 2026, Pasithea Therapeutics received a Nasdaq notice that its common...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/pasithea-therapeutics-receives-nasdaq-minimum-bid-price-notice?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/pasithea-therapeutics-receives-nasdaq-minimum-bid-price-notice?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","KTTA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613904682","title":"Nasdaq flags Pasithea Therapeutics for failing $1 minimum bid rule","url":"https://stock-news.laohu8.com/highlight/detail?id=2613904682","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613904682?lang=en_us&edition=fundamental","pubTime":"2026-02-21 06:01","pubTimestamp":1771624887,"startTime":"0","endTime":"0","summary":"Pasithea Therapeutics Corp. said it received a Nasdaq notice stating it is not in compliance with the exchange’s $1.00 minimum bid price requirement for continued listing on the Nasdaq Capital Market. The company has until August 19, 2026 to regain compliance, generally by maintaining a closing bid price at or above $1.00 for at least 10 consecutive business days, and it may seek an additional compliance period if eligible.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pasithea Therapeutics Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 20, 2026, and is solely respo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260220:nNDL84GF1g:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KTTA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612519974","title":"Pasithea Therapeutics to Present at Oppenheimer Healthcare Life Sciences Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2612519974","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612519974?lang=en_us&edition=fundamental","pubTime":"2026-02-17 20:02","pubTimestamp":1771329728,"startTime":"0","endTime":"0","summary":"Pasithea Therapeutics Corporation  will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on Thursday, February 26, 2026, from 4:00-4:30 PM ET in Track 2. The virtual presentation by CEO Tiago Reis Marques can be accessed through a live webcast on the Events page in the Investors section of the Company's website, with a replay available following the event. The webcast may be viewed here.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pasithea Therapeutics Corporation published the original content used to generate this news brief via GlobeNewswire  on February 17, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nNDL890MjR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IE00BKPKM429.USD","LU2210150020.SGD","LU2095319765.USD","SG9999014021.USD","BK4585","LU0314104364.USD","LU2210149790.SGD","IE00BGHQF748.EUR","SG9999014013.SGD","SG9999014039.USD","SG9999014005.SGD","KTTA","IE00B64PRP62.GBP","BK4588","IE00B3QW5Z07.USD","BK4112"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2607728940","title":"Pasithea Therapeutics Corporation Held Special Shareholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2607728940","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607728940?lang=en_us&edition=fundamental","pubTime":"2026-01-29 05:19","pubTimestamp":1769635150,"startTime":"0","endTime":"0","summary":"Pasithea Therapeutics Corporation held a Special Meeting of Stockholders on January 28, 2026. Stockholders approved an amendment to increase the number of authorized shares of common stock from 100,000,000 to 500,000,000. An amendment to the 2023 Stock Incentive Plan, increasing the number of shares authorized for issuance under the plan, was also approved.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pasithea Therapeutics Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 28, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260128:nNDL32vqKj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KTTA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603184536","title":"Pasithea Therapeutics: Buy Rating on Differentiated PAS-004, 2026 Clinical Catalysts, and Strengthened Cash Runway","url":"https://stock-news.laohu8.com/highlight/detail?id=2603184536","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603184536?lang=en_us&edition=fundamental","pubTime":"2026-01-14 19:56","pubTimestamp":1768391813,"startTime":"0","endTime":"0","summary":"Analyst Sara Nik of H.C. Wainwright reiterated a Buy rating on Pasithea Therapeutics Corp, retaining the price target of $3.00. Sara Nik has given ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/pasithea-therapeutics-buy-rating-on-differentiated-pas-004-2026-clinical-catalysts-and-strengthened-cash-runway-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/pasithea-therapeutics-buy-rating-on-differentiated-pas-004-2026-clinical-catalysts-and-strengthened-cash-runway-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KTTA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603686640","title":"Pasithea Therapeutics Announces Data Release Timeline for PAS-004 Clinical Trials in NF1 and Advanced Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2603686640","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603686640?lang=en_us&edition=fundamental","pubTime":"2026-01-13 20:02","pubTimestamp":1768305720,"startTime":"0","endTime":"0","summary":"Pasithea Therapeutics Corporation announced updates on its clinical development programs for PAS-004, a next-generation oral macrocyclic MEK inhibitor. The company has completed enrollment of 12 patients in the first four dose cohorts of its Phase 1/1b clinical trial  in adult patients with neurofibromatosis type 1 associated plexiform neurofibromas . Pasithea plans to present safety, tolerability, pharmacokinetic, and efficacy data, including six-month outcomes for both plexiform and cutaneous neurofibromas, in the second half of 2026. Additionally, in its ongoing Phase 1 clinical trial in advanced cancer patients , Pasithea expects to present longer-term follow-up data from Cohorts 4 through 8 in the second quarter of 2026. Results from these studies have not yet been presented and will be released in the future according to the company’s outlined timelines.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nNDL8jYNDG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","IE00BKPKM429.USD","SG9999014013.SGD","SG9999014021.USD","LU0314104364.USD","LU2210149790.SGD","IE00B3QW5Z07.USD","KTTA","LU2210150020.SGD","SG9999014005.SGD","LU2095319765.USD","BK4588","BK4139","SG9999014039.USD","BK4112","IE00B64PRP62.GBP","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603686669","title":"Pasithea Therapeutics Corp - to Present Nf1-Pn Study Data in H2 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2603686669","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603686669?lang=en_us&edition=fundamental","pubTime":"2026-01-13 20:01","pubTimestamp":1768305696,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nFWN3YD1RI:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KTTA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603686905","title":"Pasithea Therapeutics Provides Outlook on PAS-004 Clinical Programs and Data Release Timelines","url":"https://stock-news.laohu8.com/highlight/detail?id=2603686905","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603686905?lang=en_us&edition=fundamental","pubTime":"2026-01-13 20:01","pubTimestamp":1768305660,"startTime":"0","endTime":"0","summary":"MIAMI, Jan.  13, 2026  (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation oral m","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/13/3217645/0/en/Pasithea-Therapeutics-Provides-Outlook-on-PAS-004-Clinical-Programs-and-Data-Release-Timelines.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4218","BK4181","BK4023","LU1169590202.USD","LU1169589451.USD","KTTA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2602607425","title":"Pasithea Therapeutics Unveils Investor Presentation Highlighting Next-Generation MEK Inhibitor PAS-004 for Cancer and NF1","url":"https://stock-news.laohu8.com/highlight/detail?id=2602607425","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602607425?lang=en_us&edition=fundamental","pubTime":"2026-01-12 12:26","pubTimestamp":1768191993,"startTime":"0","endTime":"0","summary":"Pasithea Therapeutics Corporation has released a new investor presentation outlining the company’s current pipeline and ongoing clinical programs. The presentation provides updates on the development, manufacturing, and commercialization plans for its product candidates, including details on PAS-004 and the design and enrollment of its ongoing Phase 1 and Phase 1/b clinical trials in advanced cancer patients. Information is also provided regarding cash needs, projected cash runway, and current operating plans. The document includes data on market size and industry comparisons. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pasithea Therapeutics Corporation published the origi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDL2sSMVD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KTTA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2592190534","title":"Pasithea Therapeutics Corporation Announces Date for Upcoming Special Meeting of Stockholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2592190534","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592190534?lang=en_us&edition=fundamental","pubTime":"2025-12-20 05:31","pubTimestamp":1766179912,"startTime":"0","endTime":"0","summary":"Pasithea Therapeutics Corp. has announced that it will hold a Special Meeting of Stockholders in a virtual format on January 28, 2026. During the meeting, stockholders will vote on proposals including an increase to the company’s authorized shares and an amendment to the 2023 Incentive Plan.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pasithea Therapeutics Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 19, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nNDL9RgcVW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KTTA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2589584453","title":"Pasithea Therapeutics Initiated at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2589584453","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589584453?lang=en_us&edition=fundamental","pubTime":"2025-12-08 20:52","pubTimestamp":1765198320,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/KTTA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 08, 2025 07:52 ET (12:52 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KTTA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2589330469","title":"HC Wainwright Initiates Coverage on Pasithea Therapeutics With Buy Rating, $3 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2589330469","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589330469?lang=en_us&edition=fundamental","pubTime":"2025-12-08 20:23","pubTimestamp":1765196627,"startTime":"0","endTime":"0","summary":"Pasithea Therapeutics (KTTA) has an average rating of Buy and mean price target of $3, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major b","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","KTTA"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.pasithea.com","stockEarnings":[{"period":"1week","weight":-0.03},{"period":"1month","weight":-0.0368},{"period":"3month","weight":-0.1992},{"period":"6month","weight":-0.1536},{"period":"1year","weight":-0.5801},{"period":"ytd","weight":-0.4661}],"compareEarnings":[{"period":"1week","weight":0.0005},{"period":"1month","weight":0.126},{"period":"3month","weight":0.0253},{"period":"6month","weight":0.0433},{"period":"1year","weight":0.2837},{"period":"ytd","weight":0.0435}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.182441},{"month":2,"riseRate":0.4,"avgChangeRate":-0.152614},{"month":3,"riseRate":0.4,"avgChangeRate":-0.0152},{"month":4,"riseRate":0.2,"avgChangeRate":0.003185},{"month":5,"riseRate":0.25,"avgChangeRate":-0.227944},{"month":6,"riseRate":0.5,"avgChangeRate":0.06208},{"month":7,"riseRate":1,"avgChangeRate":0.10295},{"month":8,"riseRate":0.5,"avgChangeRate":-0.003687},{"month":9,"riseRate":0.5,"avgChangeRate":-0.003936},{"month":10,"riseRate":0.2,"avgChangeRate":-0.132455},{"month":11,"riseRate":0.4,"avgChangeRate":0.147256},{"month":12,"riseRate":0.4,"avgChangeRate":-0.165941}],"exchange":"NASDAQ","name":"Pasithea Therapeutics Corp.","nameEN":"Pasithea Therapeutics Corp."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Pasithea Therapeutics Corp.(KTTA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Pasithea Therapeutics Corp.(KTTA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Pasithea Therapeutics Corp.,KTTA,Pasithea Therapeutics Corp.股票,Pasithea Therapeutics Corp.股票老虎,Pasithea Therapeutics Corp.股票老虎国际,Pasithea Therapeutics Corp.行情,Pasithea Therapeutics Corp.股票行情,Pasithea Therapeutics Corp.股价,Pasithea Therapeutics Corp.股市,Pasithea Therapeutics Corp.股票价格,Pasithea Therapeutics Corp.股票交易,Pasithea Therapeutics Corp.股票购买,Pasithea Therapeutics Corp.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Pasithea Therapeutics Corp.(KTTA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Pasithea Therapeutics Corp.(KTTA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}